ESPE Abstracts (2021) 94 P2-386

Pituitary, neuroendocrinology and puberty

Blood Pressure in Girls with Central Precocious Puberty and GnRH Analog Therapy

Naama Fisch Shvalb1,2, Hadas Alfandary Harani2,3, Miriam Davidovits2, Nir Shvalb4, Sharon Demol Eliaz1,2, Michal Yackobovitch Gavan1,5, Moshe Phillip1,2 & Liat de Vries1,2

10 views


1The Jesse Z. and Lea Shafer Institute of Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children’s Medical Center of Israel, Petach Tikva, Israel; 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 3Institute of Nephrology, Schneider Children’s Medical Center of Israel, Petach Tikva, Israel; 4Faculty of Engineering, Ariel University, Ariel, Israel; 5Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel


Objectives: Several case reports describe hypertension (HTN) in children treated with GnRH analogs for central precocious puberty (CPP). However, relevant data on blood pressure (BP) under GnRH analog treatment are scarce. We evaluated BP among girls with idiopathic CPP and early puberty (EP) before, during and after GnRH analog therapy, and examined associations of BP with clinical parameters.

Design: A retrospective longitudinal cohort study in a tertiary pediatric endocrinology institute.

Methods: Demographic, anthropometric, clinical and laboratory data were collected from electronic files of 112 girls treated with GnRH analog for idiopathic CPP (n = 81) or EP (n = 31) (the study group), and 37 healthy pre-pubertal controls. BP measurements from regular clinic visits were expressed as percentiles adjusted for gender, height and age. Data at baseline, under therapy and off-therapy were compared.

Results: At presentation, mean BP values were above the 50th percentile in all three subgroups; mean values of the study group did not differ significantly from those of the controls. At diagnosis, 53 patients (47%) of the study group had normal BP values, 16 (14%) had elevated BP values and 43 (39%) had values within the range defined as HTN. The mean systolic and diastolic BP percentiles at first measurement under treatment remained unchanged. After treatment cessation, the mean systolic, but not diastolic, BP percentile was lower than baseline (n = 47, P = 0.006). In the study group, girls with baseline BP >90th percentile had lower mean birthweight (P = 0.01) and a higher mean BMI-standard deviation score (P = 0.01). Girls with baseline BP >90th percentile were not different from those with BP < 90th percentile in mean age at onset of puberty, height-SDS, Tanner stage, bone age SDS, peak LH, E2, DHEA-S or androstenedione levels at diagnosis.

Conclusions: At presentation, girls with CPP and EP had BP values similar to pre-pubertal controls. BP did not change during GnRH analog therapy, but the mean systolic BP percentile decreased off-treatment. The stability of mean BP percentile during treatment is reassuring.

Volume 94

59th Annual ESPE (ESPE 2021 Online)

Online,
22 Sep 2021 - 26 Sep 2021

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts

No recent abstracts.